Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BE.1.2NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-21956.6US
BE.1.2NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BE.1.2NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BE.1.2ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
AY.16.1 (Delta)ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-17266.7Germany
AY.16.1 (Delta)ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
AY.16.1 (Delta)NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-21977.3China
AY.16.1 (Delta)NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
AY.16.1 (Delta)NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
AY.16.1 (Delta)NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
AY.16.1 (Delta)NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
AY.16.1 (Delta)ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.9.7ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BA.2.9.7ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.9.7NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.9.7NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.9.7NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.9.7NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.2.9.7NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BA.2.9.7ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.72ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BA.2.72ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.72NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.72NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.72NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.72NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.2.72NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BA.2.72ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.7ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-19265.7Germany
BA.2.7ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.7NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.7NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.7NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.7NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.2.7NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BA.2.7ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.20ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BA.2.20ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.20NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.20NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.20NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.20NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
BA.2.20NHKU-NTAATCAGACAAGGAACTGATTA2231.822914529166F-18800.2Hong Kong
BA.2.20ORF1abNIID WH-1 F509R854CAGAAGTTGTTATCGACATAGC2240.91837816R-21257.9Japan
BA.2.73ORF1abCharité-ORF1bGTGARATGGTCATGTGTGGCGG2254.551543115452F-20262.1Germany
BA.2.73ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-23527.6Germany
BA.2.73NCN-CDC-NGGGGAACTTCTCCTGCTAGAAT22502888128902F-17926.1China
BA.2.73NCN-CDC-NCAGACATTTTGCTCTCAAGCTG2245.452897928958R-23140.2China
BA.2.73NUS-CDC-N-3GGGAGCCTTGAATACACCAAAA2245.452868128702F-22824.1US
BA.2.73NYoung-NCTCAGTCCAAGATGGTATTTCT2240.912858328604F-21953.9Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used